Non small cell lung cancer screening: Difference between revisions
No edit summary |
Shanshan Cen (talk | contribs) No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Non small cell lung cancer}} | {{Non small cell lung cancer}} | ||
{{ | {{CMG}}; {{AE}} {{SC}} | ||
==Overview== | |||
Lung cancer screening is a strategy used to identify early [[lung cancer]] in people, before they develop symptoms. [[Screening (medicine)|Screening]] refers to the use of medical tests to detect disease in asymptomatic people. Screening studies for lung cancer have only been done in high risk populations, such as smokers and workers with occupational exposure to certain substances. This is because radiation exposure from screening could actually induce carcinogenesis cancer formation in a small percentage of screened subjects, so this risk should be mitigated by a (relatively) high prevalence of lung cancer in the population being screened. A pulmonary nodule larger than 5 to 6 mm is considered a positive result for screening with [[x-ray]] or [[computed tomography]].<ref name="pmid23420233">{{cite journal| author=Henschke CI, Yip R, Yankelevitz DF, Smith JP, International Early Lung Cancer Action Program Investigators*| title=Definition of a positive test result in computed tomography screening for lung cancer: a cohort study. | journal=Ann Intern Med | year= 2013 | volume= 158 | issue= 4 | pages= 246-52 | pmid=23420233 | doi=10.7326/0003-4819-158-4-201302190-00004 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23420233 }} </ref> | |||
==Practice Guidelines== | |||
===Current Guidelines=== | |||
* In 2013, a clinical practice guideline by the U.S. Preventive Services Task Force ([[USPSTF]]) recommended screening for lung cancer among smokers and former smokers who are between 55 to 80 years old and who have smoked 30 pack-years or more and either continue to smoke or have quit within the past 15 years (grade B recommendation).<ref name="www.uspreventiveservicestaskforce.org">{{Cite web | last = | first = | title = http://www.uspreventiveservicestaskforce.org/uspstf13/lungcan/lungcanfinalrs.htm | url = http://www.uspreventiveservicestaskforce.org/uspstf13/lungcan/lungcanfinalrs.htm | publisher = | date = | accessdate = 31 December 2013 }}</ref> | |||
* [[Clinical practice guideline]]s issued by the [[American College of Chest Physicians]] in 2013 recommend<ref name="pmid23649455">{{cite journal| author=Detterbeck FC, Mazzone PJ, Naidich DP, Bach PB| title=Screening for Lung Cancer: Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. | journal=Chest | year= 2013 | volume= 143 | issue= 5 Suppl | pages= e78S-92S | pmid=23649455 | doi=10.1378/chest.12-2350 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23649455 }} [http://general-medicine.jwatch.org/cgi/content/full/2013/522/2 Summary in JournalWatch]</ref>: "For smokers and former smokers who are age 55 to 74 and who have smoked for 30 pack-years or more and either continue to smoke or have quit within the past 15 years, we suggest that annual screening with LDCT should be offered in settings that can deliver the comprehensive care provided to NLST participants." | |||
===Previous Guidelines=== | |||
* In 2004, a clinical practice guideline by the [http://www.ahrq.gov/clinic/uspstfix.htm U.S. Preventive Services Task Force (USPSTF)] gave a [http://www.ahrq.gov/clinic/3rduspstf/ratings.htm grade I recommendation] indicating that "the evidence is insufficient to recommend for or against screening asymptomatic persons for lung cancer".<ref name="pmid15126258">{{cite journal |author=U.S. Preventive Services Task Force |title=Lung cancer screening: recommendation statement |journal=Ann. Intern. Med. |volume=140 |issue=9 |pages=738-9 |year=2004 |pmid=15126258 |doi=|url=http://www.annals.org/cgi/content/full/140/9/738}}</ref><ref name="pmid15126259">{{cite journal |author=Humphrey LL, Teutsch S, Johnson M |title=Lung cancer screening with sputum cytologic examination, chest radiography, and computed tomography: an update for the U.S. Preventive Services Task Force |journal=Ann. Intern. Med. |volume=140 |issue=9 |pages=740-53 |year=2004 |pmid=15126259 |doi=|url=http://www.annals.org/cgi/content/full/140/9/740}}</ref> | |||
* In 2007, a [[clinical practice guideline]] by [[American College of Chest Physicians]] recommended not to screen for lung cancer.<ref name="pmid17873156">{{cite journal |author=Alberts WM |title=Diagnosis and Management of Lung Cancer Executive Summary: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) |journal= |volume=132 |issue=3_suppl |pages=1S–19S |year=2007 |pmid=17873156 |doi=10.1378/chest.07-1860}}</ref> | |||
==Studies of efficacy== | |||
Regular chest radiography and sputum examination programs were not effective in reducing mortality from lung cancer.<ref name="pmid14973979">{{cite journal |author=Manser RL, Irving LB, Stone C, Byrnes G, Abramson M, Campbell D |title=Screening for lung cancer |journal=Cochrane database of systematic reviews (Online) |volume= |issue=1 |pages=CD001991 |year=2004 |pmid=14973979 |doi=10.1002/14651858.CD001991.pub2}}</ref> Earlier studies (Mayo Lung Project and Czechoslovakia lung cancer screening study, combining over 17,000 smokers) showed earlier detection of lung cancer was possible but mortality was not improved. Simply detecting a tumor at an earlier stage may not necessarily yield improved mortality. For example, plain radiography resulted in increased time from diagnosis of cancer until death and those cancers being detected by screening tended to be earlier stages. However, these patients continued to die at the same rate as those who are not screened. At present, no professional or specialty organization advocates screening for lung cancer outside of clinical trials. | |||
A computed tomography (CT) scan can uncover tumors not yet visible on an X-ray. CT scanning is now being actively evaluated as a screening tool for lung cancer in high risk patients, and it is showing promising results. The USA-based National Cancer Institute is currently completing a randomized trial comparing CT scans with chest radiographs. Several single-institution trials are ongoing around the world. | |||
The International Early Lung Cancer Action Project is a cohort study 31,000 high-risk patients that found benefit from screening.<ref name="pmid17065637">{{cite journal |author=Henschke CI, Yankelevitz DF, Libby DM, Pasmantier MW, Smith JP, Miettinen OS |title=Survival of patients with stage I lung cancer detected on CT screening |journal=N. Engl. J. Med. |volume=355 |issue=17 |pages=1763-71 |year=2006 |pmid=17065637 |doi=10.1056/NEJMoa060476}}</ref> In this study 85% of the 484 detected lung cancers were stage I and thus highly treatable. Mathematically these stage I patients would have an expected 10-year survival of 88%. However, there was no randomization of patients (all received CT scans and there was no comparison group receiving only x-rays) and the patients were not actually followed out to 10 years post detection (the median followup was 40 months). | |||
A cohort of 3,200 current or former smokers found no benefit. These patients were screened for 4 years and offered 3 or 4 CT scans. Lung cancer diagnoses were 3 times as high, and surgeries were 10 times as high, as predicted by a model, but there were no significant differences between observed and expected numbers of advanced cancers or deaths.<ref name="pmid17341709">{{cite journal |author=Bach PB, Jett JR, Pastorino U, Tockman MS, Swensen SJ, Begg CB |title=Computed tomography screening and lung cancer outcomes |journal=JAMA |volume=297 |issue=9 |pages=953-61 |year=2007 |pmid=17341709 |doi=10.1001/jama.297.9.953}}</ref> | |||
Subsequent [[randomized controlled trial]]s have been performed or are in progress<ref name="pmid15603850">{{cite journal |author=Gohagan JK, Marcus PM, Fagerstrom RM, ''et al'' |title=Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest X-ray screening for lung cancer |journal=Lung Cancer |volume=47 |issue=1 |pages=9-15 |year=2005 |pmid=15603850 |doi=10.1016/j.lungcan.2004.06.007}}</ref>. | |||
* The National Lung Screening Trial (NLST) reported reduction advanced-stage cancers diagnosed.<ref name="pmid24004119">{{cite journal| author=Aberle DR, DeMello S, Berg CD, Black WC, Brewer B, Church TR et al.| title=Results of the two incidence screenings in the National Lung Screening Trial. | journal=N Engl J Med | year= 2013 | volume= 369 | issue= 10 | pages= 920-31 | pmid=24004119 | doi=10.1056/NEJMoa1208962 | pmc=PMC4307922 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24004119 }} </ref> | |||
* The DANTE trial has been inconclusive.<ref name="pmid25760561">{{cite journal| author=Infante M, Cavuto S, Lutman FR, Passera E, Chiarenza M, Chiesa G et al.| title=Long-Term Follow-up Results of the DANTE Trial, a Randomized Study of Lung Cancer Screening with Spiral Computed Tomography. | journal=Am J Respir Crit Care Med | year= 2015 | volume= 191 | issue= 10 | pages= 1166-75 | pmid=25760561 | doi=10.1164/rccm.201408-1475OC | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25760561 }} </ref> | |||
==Screening for Lung Cancer U.S. Preventive Services Task Force Recommendation Statement 2013 (DO NOT EDIT)<ref name="www.uspreventiveservicestaskforce.org">{{Cite web | last = | first = | title = http://www.uspreventiveservicestaskforce.org/uspstf13/lungcan/lungcanfinalrs.htm | url = http://www.uspreventiveservicestaskforce.org/uspstf13/lungcan/lungcanfinalrs.htm | publisher = | date = | accessdate = 31 December 2013 }}</ref>== | |||
{|class="wikitable" | |||
|- | |||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.''' The USPSTF recommends annual screening for lung cancer with low-dose [[CT|computed tomography]] (LDCT) in adults aged 55 to 80 years who have a 30 pack-year [[smoking]] history and currently smoke or have quit within the past 15 years. Screening should be discontinued once a person has not smoked for 15 years or develops a health problem that substantially limits life expectancy or the ability or willingness to have curative lung surgery. ''([[USPSTF guidelines classification scheme#Evidence Quality Rating|Grade B]])''<nowiki>"</nowiki> | |||
|- | |||
|} | |||
==References== | ==References== |
Revision as of 20:02, 21 December 2015
Non Small Cell Lung Cancer Microchapters |
Differentiating Non Small Cell Lung Cancer from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Non small cell lung cancer screening On the Web |
American Roentgen Ray Society Images of Non small cell lung cancer screening |
Directions to Hospitals Treating Non small cell carcinoma of the lung |
Risk calculators and risk factors for Non small cell lung cancer screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shanshan Cen, M.D. [2]
Overview
Lung cancer screening is a strategy used to identify early lung cancer in people, before they develop symptoms. Screening refers to the use of medical tests to detect disease in asymptomatic people. Screening studies for lung cancer have only been done in high risk populations, such as smokers and workers with occupational exposure to certain substances. This is because radiation exposure from screening could actually induce carcinogenesis cancer formation in a small percentage of screened subjects, so this risk should be mitigated by a (relatively) high prevalence of lung cancer in the population being screened. A pulmonary nodule larger than 5 to 6 mm is considered a positive result for screening with x-ray or computed tomography.[1]
Practice Guidelines
Current Guidelines
- In 2013, a clinical practice guideline by the U.S. Preventive Services Task Force (USPSTF) recommended screening for lung cancer among smokers and former smokers who are between 55 to 80 years old and who have smoked 30 pack-years or more and either continue to smoke or have quit within the past 15 years (grade B recommendation).[2]
- Clinical practice guidelines issued by the American College of Chest Physicians in 2013 recommend[3]: "For smokers and former smokers who are age 55 to 74 and who have smoked for 30 pack-years or more and either continue to smoke or have quit within the past 15 years, we suggest that annual screening with LDCT should be offered in settings that can deliver the comprehensive care provided to NLST participants."
Previous Guidelines
- In 2004, a clinical practice guideline by the U.S. Preventive Services Task Force (USPSTF) gave a grade I recommendation indicating that "the evidence is insufficient to recommend for or against screening asymptomatic persons for lung cancer".[4][5]
- In 2007, a clinical practice guideline by American College of Chest Physicians recommended not to screen for lung cancer.[6]
Studies of efficacy
Regular chest radiography and sputum examination programs were not effective in reducing mortality from lung cancer.[7] Earlier studies (Mayo Lung Project and Czechoslovakia lung cancer screening study, combining over 17,000 smokers) showed earlier detection of lung cancer was possible but mortality was not improved. Simply detecting a tumor at an earlier stage may not necessarily yield improved mortality. For example, plain radiography resulted in increased time from diagnosis of cancer until death and those cancers being detected by screening tended to be earlier stages. However, these patients continued to die at the same rate as those who are not screened. At present, no professional or specialty organization advocates screening for lung cancer outside of clinical trials.
A computed tomography (CT) scan can uncover tumors not yet visible on an X-ray. CT scanning is now being actively evaluated as a screening tool for lung cancer in high risk patients, and it is showing promising results. The USA-based National Cancer Institute is currently completing a randomized trial comparing CT scans with chest radiographs. Several single-institution trials are ongoing around the world.
The International Early Lung Cancer Action Project is a cohort study 31,000 high-risk patients that found benefit from screening.[8] In this study 85% of the 484 detected lung cancers were stage I and thus highly treatable. Mathematically these stage I patients would have an expected 10-year survival of 88%. However, there was no randomization of patients (all received CT scans and there was no comparison group receiving only x-rays) and the patients were not actually followed out to 10 years post detection (the median followup was 40 months).
A cohort of 3,200 current or former smokers found no benefit. These patients were screened for 4 years and offered 3 or 4 CT scans. Lung cancer diagnoses were 3 times as high, and surgeries were 10 times as high, as predicted by a model, but there were no significant differences between observed and expected numbers of advanced cancers or deaths.[9]
Subsequent randomized controlled trials have been performed or are in progress[10].
- The National Lung Screening Trial (NLST) reported reduction advanced-stage cancers diagnosed.[11]
- The DANTE trial has been inconclusive.[12]
Screening for Lung Cancer U.S. Preventive Services Task Force Recommendation Statement 2013 (DO NOT EDIT)[2]
"1. The USPSTF recommends annual screening for lung cancer with low-dose computed tomography (LDCT) in adults aged 55 to 80 years who have a 30 pack-year smoking history and currently smoke or have quit within the past 15 years. Screening should be discontinued once a person has not smoked for 15 years or develops a health problem that substantially limits life expectancy or the ability or willingness to have curative lung surgery. (Grade B)" |
References
- ↑ Henschke CI, Yip R, Yankelevitz DF, Smith JP, International Early Lung Cancer Action Program Investigators* (2013). "Definition of a positive test result in computed tomography screening for lung cancer: a cohort study". Ann Intern Med. 158 (4): 246–52. doi:10.7326/0003-4819-158-4-201302190-00004. PMID 23420233.
- ↑ 2.0 2.1 "http://www.uspreventiveservicestaskforce.org/uspstf13/lungcan/lungcanfinalrs.htm". Retrieved 31 December 2013. External link in
|title=
(help) - ↑ Detterbeck FC, Mazzone PJ, Naidich DP, Bach PB (2013). "Screening for Lung Cancer: Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines". Chest. 143 (5 Suppl): e78S–92S. doi:10.1378/chest.12-2350. PMID 23649455. Summary in JournalWatch
- ↑ U.S. Preventive Services Task Force (2004). "Lung cancer screening: recommendation statement". Ann. Intern. Med. 140 (9): 738–9. PMID 15126258.
- ↑ Humphrey LL, Teutsch S, Johnson M (2004). "Lung cancer screening with sputum cytologic examination, chest radiography, and computed tomography: an update for the U.S. Preventive Services Task Force". Ann. Intern. Med. 140 (9): 740–53. PMID 15126259.
- ↑ Alberts WM (2007). "Diagnosis and Management of Lung Cancer Executive Summary: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition)". 132 (3_suppl): 1S–19S. doi:10.1378/chest.07-1860. PMID 17873156.
- ↑ Manser RL, Irving LB, Stone C, Byrnes G, Abramson M, Campbell D (2004). "Screening for lung cancer". Cochrane database of systematic reviews (Online) (1): CD001991. doi:10.1002/14651858.CD001991.pub2. PMID 14973979.
- ↑ Henschke CI, Yankelevitz DF, Libby DM, Pasmantier MW, Smith JP, Miettinen OS (2006). "Survival of patients with stage I lung cancer detected on CT screening". N. Engl. J. Med. 355 (17): 1763–71. doi:10.1056/NEJMoa060476. PMID 17065637.
- ↑ Bach PB, Jett JR, Pastorino U, Tockman MS, Swensen SJ, Begg CB (2007). "Computed tomography screening and lung cancer outcomes". JAMA. 297 (9): 953–61. doi:10.1001/jama.297.9.953. PMID 17341709.
- ↑ Gohagan JK, Marcus PM, Fagerstrom RM; et al. (2005). "Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest X-ray screening for lung cancer". Lung Cancer. 47 (1): 9–15. doi:10.1016/j.lungcan.2004.06.007. PMID 15603850.
- ↑ Aberle DR, DeMello S, Berg CD, Black WC, Brewer B, Church TR; et al. (2013). "Results of the two incidence screenings in the National Lung Screening Trial". N Engl J Med. 369 (10): 920–31. doi:10.1056/NEJMoa1208962. PMC 4307922. PMID 24004119.
- ↑ Infante M, Cavuto S, Lutman FR, Passera E, Chiarenza M, Chiesa G; et al. (2015). "Long-Term Follow-up Results of the DANTE Trial, a Randomized Study of Lung Cancer Screening with Spiral Computed Tomography". Am J Respir Crit Care Med. 191 (10): 1166–75. doi:10.1164/rccm.201408-1475OC. PMID 25760561.